Over the past 50 years antibodies have broken through as a leading technology for developing diagnostics and therapeutics. But we are reaching its limits in certain applications. Laboratory testing takes days to get test results and portable tests are unreliable and don’t test many things we want to test.

Cracking the problem of aptamer commercialisation with artificial intelligence will enable the detection and targeting of almost any molecule of interest. This will open up a plethora of markets and products within targeted therapeutics and preventative diagnostics; technologies that are expected have a $1.2 trillion direct global economic impact per year according to McKinsey & Co.

PentaBind is an AI drug and diagnostics discovery company using artificial intelligence to design aptamers (short strands of synthetic DNA) which will help to overcome the challenges of laboratory-based aptamer development.